The Case Western Reserve University Cancer Research Center is a multidisciplinary clinical and laboratory research center, combining the resources and expertise at Case Western Reserve University School of Medicine and its major affiliated Hospitals, University Hospitals of Cleveland, MetroHealth Medical Center and the Cleveland Veterans Administration Medical Center. The objectives of the Case Western Reserve University Cancer Research Center are: 1. To improve the prevention, diagnosis and therapy of cancer through rearch; 2. To rapidly develop the clinical applications of research discoveries and to make these applications available to the residents of the northeast Ohio region as quickly as possible; 3. To provide the stimulation and support facilities for the development of coordinated, interdisciplinary cancer research that most effectively utilizes the resources and expertise available at the associated institutions. 4. To provide all the services and benefits of an NIH designated Comprehensive Cancer Center to northeast Ohio and the surrounding region. The goals of the Center are accomplished by activities in 7 active programs, 1 developing program and 8 shared resources. PROGRAMS 1. Molecular Biology of Oncogenesis 2. Molecular Virology and AIDS 3. Hematopoietic and Immune Cell Biology 4. Radiation Biology 5. Environmental Carcinogenesis 6. Tumor Metabolism 7. Clinical Trials 8. Prostate Cancer Biology SHARED RESOURCES 1. Molecular Biology 2. Tissue Culture Support 3. Flow Cytometry 4. Radiation Services 5. Histology 6. Athymic Animal Facility 7. Hematopoietic Stem Cell Facility 8. Biostatistics and Clinical Trial

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-06
Application #
3101822
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1991-09-30
Project End
1995-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications